Tubize Financial Statements From 2010 to 2024
| TUB Stock | EUR 138.40 2.20 1.62% |
Check Tubize Fin financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tubize Fin's main balance sheet or income statement drivers, such as , as well as many indicators such as . Tubize financial statements analysis is a perfect complement when working with Tubize Fin Valuation or Volatility modules.
Tubize |
Tubize Fin Company Return On Equity Analysis
Tubize Fin's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Tubize Fin Return On Equity | 0.0988 |
Most of Tubize Fin's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tubize Fin is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Tubize Fin has a Return On Equity of 0.0988. This is 100.41% lower than that of the Pharmaceuticals sector and 100.27% lower than that of the Health Care industry. The return on equity for all Belgium stocks is 131.87% lower than that of the firm.
Tubize Fin Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Tubize Fin's current stock value. Our valuation model uses many indicators to compare Tubize Fin value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tubize Fin competition to find correlations between indicators driving Tubize Fin's intrinsic value. More Info.Tubize Fin is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Tubize Fin's earnings, one of the primary drivers of an investment's value.About Tubize Fin Financial Statements
Tubize Fin shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Tubize Fin investors may analyze each financial statement separately, they are all interrelated. The changes in Tubize Fin's assets and liabilities, for example, are also reflected in the revenues and expenses on on Tubize Fin's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Financire de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. The companys products in pipeline include UCB0942 for drug resistant epilepsy UCB3491 for infantile epilepsy UCB0599 for Parkinsons disease UCB7858UCB0159 for auto-inflammatory diseases UCB6673 to treat immunological diseases UCB4144VR942 to treat asthma seletalisib for treating Sjrgens syndrome dapirolizumab pegol for systemic lupus erythematosus bimekizumab to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis rozanolixizumab to treat immune thrombocytopenia and myasthenia gravis and romosozumab for post-menopausal osteoporosis and osteoporosis in men. TUBIZE FIN operates under Pharmaceuticals And Biosciences classification in Belgium and is traded on Brussels Stock Exchange.
Pair Trading with Tubize Fin
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tubize Fin position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tubize Fin will appreciate offsetting losses from the drop in the long position's value.Moving against Tubize Stock
The ability to find closely correlated positions to Tubize Fin could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tubize Fin when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tubize Fin - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tubize Fin to buy it.
The correlation of Tubize Fin is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tubize Fin moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tubize Fin moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tubize Fin can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Tubize Stock Analysis
When running Tubize Fin's price analysis, check to measure Tubize Fin's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tubize Fin is operating at the current time. Most of Tubize Fin's value examination focuses on studying past and present price action to predict the probability of Tubize Fin's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tubize Fin's price. Additionally, you may evaluate how the addition of Tubize Fin to your portfolios can decrease your overall portfolio volatility.